The role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment

Economou, Evangelos K.; Oikonomou, Evangelos; Siasos, Gerasimos; Papageorgiou, Nikolaos S.; Tsalamandris, Sotiris; Mourouzis, Konsantinos; Papaioanou, Spyridon; Tousoulis, Dimitris

doi:10.1016/j.atherosclerosis.2015.06.037

Cited by 92 publications

(73 citation statements)

References 133 publications

(142 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, we found none of the typically reported atherosclerosis-related miRs, as miR-126, miR-21, miR-92a, miR-19a, miR-221 and miR-222 (reviewed in [65]), to be associated with future AMI in our study. We believe the reason might, in part, be explained by the platform used for the miR analysis and also the choice of normalization method.…”

mentioning

confidence: 58%

Circulating microRNAs predict future fatal myocardial infarction in healthy individuals – The HUNT study

Bye

Røsjø

Nauman

et al. 2016

Journal of Molecular and Cellular Cardiology

115

View full text Add to dashboard Cite

mentioning

confidence: 58%

Circulating microRNAs predict future fatal myocardial infarction in healthy individuals – The HUNT study

Bye

Røsjø

Nauman

et al. 2016

Journal of Molecular and Cellular Cardiology

115

View full text Add to dashboard Cite

“…MiRNA-155 was found to be either upregulated or downregulated in coronary artery disease patients and thus might promote or prevent CAD. These conflicting results of miRNA-155 in the pathophysiology of atherosclerosis related ischemic heart diseases indicate the complexity of this multifunctional molecule in regulation of cardiovascular remodeling induced by atherogenesis 26 . The cause of this inconsistence might be due to different pathological stages of the disease.…”

mentioning

confidence: 99%

MicroRNA-155 in patients with Chronic Stable Angina

Elshafae

Sabry

Salem

et al. 2017

AABS

View full text Add to dashboard Cite

Study Design: This observational cross-sectional study included fifty persons who were enrolled for coronary angiography due to suspicion of coronary artery disease at Cardiac Catheterization Unit, Department of cardiology, Benha University Hospital from february 2016 until august ABSTRACTBackground: Atherosclerotic cardiovascular disease is a chronic inflammatory disease and one of the major causes of death worldwide. MicroRNAs are associated with many physiological and pathological situations as inflammation and cardiovascular disease. The communication between microRNAs, inflammation, and atherosclerosis, drive attention to the possibility that inflammation-related microRNAs, miRNA-155, could have a role in atherosclerosis progression. Objectives:We aimed to determine the levels of circulating miRNA-155 in chronic stable angina patients and to study the impact of microRNA-155 on coronary artery disease severity and extent. Methods:MicroRNA was extracted and assessed from plasma of 50 subjects (20 normal controls and 30 patients with chronic stable angina) using quantitative reverse-transcription PCR (RT-PCR). Levels were compared in the two groups and correlated with Gensini score in the group with chronic stable angina (CSA).Results: Plasma levels of microRNA 155 were significantly lower in CSA patients (0.59±0.48, 1.94±0.76, in patients and control group respectively (P<0.001).The expression of miR-155 correlated negatively with Gensini scores (P<0.001), total cholesterol (P <0.001), LDL-c (P= 0.002) and triglycerides (P= 0.03).There was a significant difference in miRNA-155 levels among the quartiles of the CSA group (P < 0.001) denoting negative correlation between microRNA 155 and coronary artery disease extent. ROC curve showed that microRNA-155 sensitivity and specificity for the prediction of severity of atherosclerosis were 86.67% and 80% respectively. Conclusion:Plasma miRNA-155 is significantly lower in CSA angina patients and levels significantly decreases with the progression of atherosclerosis.

show abstract

“…Previously, miR-126 has been proposed as a prognostic marker of incident myocardial infarction in the general population [43], result partially confirmed by Jansen et al [44] who reported that only microvesicles-associated miR-126 and miR-199a predict the occurrence of CV events in patients with stable CAD. A more comprehensive review has been recently published [45]. …”

Section: Micrornas In Coronary Heart Diseasementioning

confidence: 99%

MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?

Frati

2016

BioMed Research International

View full text Add to dashboard Cite

Coronary artery disease (CAD) and its complication remain the leading cause of mortality in industrialized countries despite great advances in terms of diagnosis, prognosis, and treatment options. MicroRNAs (miRNAs), small noncoding RNAs, act as posttranscriptional gene expression modulators and have been implicated as key regulators in several physiological and pathological processes linked to CAD. Circulating miRNAs have been evaluated as promising novel biomarkers of CAD, acute coronary syndromes, and acute myocardial infarction, with prognostic implications. Several challenges related to technical aspects, miRNAs normalization, drugs interaction, and quality reporting of statistical multivariable analysis of the miRNAs observational studies remain unresolved. MicroRNA-based therapies in cardiovascular diseases are not ready yet for human trials but definitely appealing. Through this review we will provide clinicians with a concise overview of the pros and cons of microRNAs.

show abstract

The role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment

Cited by 92 publications

References 133 publications

Circulating microRNAs predict future fatal myocardial infarction in healthy individuals – The HUNT study

Circulating microRNAs predict future fatal myocardial infarction in healthy individuals – The HUNT study

MicroRNA-155 in patients with Chronic Stable Angina

MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?

Contact Info

Product

Resources

About